FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

biomarkers news from FierceBiotech

News

Battelle Ventures, Apax Partners spin off companies

There are two new spin-offs to announce today. First, Battelle Ventures has spun out regenerative medicine start-up NellOne Therapeutics from the U.S. Department of Energy's Oak Ridge National Read more...

FDA ready to start adding biomarker safety tests

The San Francisco Chronicle is reporting that the FDA is prepared to back a new safety standard on preclinical drugs that could--at some point--significantly reduce the time and expense of testing a Read more...

ALSO NOTED: Millipore CEO gains $3.9M comp package;Terminal cancer patients enlisted in trials; and much more...

> It may not rival the big bucks earned by Big Pharma CEOs, but Millipore chief exec Martin Madaus took home a hefty pay package last year. He earned $3.9 million in compensation in 2007. That Read more...

Genizon pockets $31M CAD in fifth round

Canada's Genizon BioSciences has garnered $31 million Canadian in its fifth round of financing. The lead investor is BTF B.V. of Haarlem, The Netherlands, which specializes in late-stage biotech Read more...
Tags: genes   Pfizer   Canada   biomarkers  

ALSO NOTED: Houston develop plots biotech park; Galvus wins EU nod; OncoMethylome inks deal with Abbott; and much more...

> A Houston developer has acquired Tanox's old headquarters--110,000 square feet on 24 acres--and plans to develop it as a biotechnology park. Tanox developed the asthma drug Xolair. Read more...

Biomarker company gains $25M in fresh backing

Rules-Based Medicine, which is hot in pursuit of new biomarkers, has received a $25 million injection of cash. Part of that money is coming from real estate billionaire Sam Zell, who is putting his Read more...

Wyeth drops Karo Bio atherosclerosis drug

Karo Bio and research partner Wyeth Pharmaceuticals have abandon development of LXR-623, a Phase I compound for atherosclerosis. According to a release, LXR-623 demonstrated efficacy on biomarkers Read more...

ALSO NOTED: Indevus gains $50M payday; Genzyme settles suit; AnGes submits ERT; and much more...

> Indevus has snared a $49.9 million milestone payment following the FDA's approval of Sanctura XR. Read more...

Press Release: Adnexus Therapeutics Announces Presentation of Phase I Results for CT-322

Press Release: Adnexus Therapeutics Announces Presentation of Phase I Results for CT-322

Read more...

ALSO NOTED: Feds ask Genentech for more merger info; Japan confirms bird flu outbreak; and much more...

> The FTC has asked for more information about Genentech's proposed merger with Tanox. Report

> Japan has confirmed the third outbreak of avian flu in poultry. Report

> The head of ArQule's scientific advisory …

Read more...
Tags: Tanox   ftc   Genentech   Avian Flu   biomarkers  

Get more biomarkers coverage at: